Skip to content

Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Robot-assisted Pancreaticoduodenectomy: a Randomized Controlled Study

Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Robot-assisted Pancreaticoduodenectomy: a Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05274789
Enrollment
300
Registered
2022-03-10
Start date
2022-04-15
Completion date
2024-04-01
Last updated
2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium in Old Age

Keywords

dexmedetomidine, robot-assisted pancreaticoduodenectomy

Brief summary

To observe the effect of intraoperative dexmedetomidine on the incidence of postoperative delirium, postoperative analgesic drug requirements and pain scores in elderly patients undergoing robot-assisted pancreaticoduodenectomy.

Detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled trial. Three hundred patients undergoing elective robotic-assisted pancreaticoduodenectomy were randomized to the intervention and control groups. Patients in the intervention group were given a loading dose of 0.6 μg/kg of dexmedetomidine by intravenous infusion within 10 minutes after intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the procedure; patients in the control group were given an equal volume of saline. Data were collected at 1-5 days and 1 month postoperative follow-up.

Interventions

DRUGDexmedetomidine

Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.

OTHERSaline

Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 65 years old * Patients undergoing elective robotic-assisted pancreaticoduodenectomy. * Written informed consent was obtained.

Exclusion criteria

* Patients with severe preoperative cognitive impairment (MMSE ≤ 20) who are unable to undergo a follow-up evaluation. * Patients with history of psychiatric or neurological disorders. * Patients with body mass index ≤ 18 or ≥ 30 * Pregnant or lactating women * Patients with severe bradycardia (heart rate less than 40 beats per minute) * Patients with pathological sinus node syndrome or grade 2 or greater AV block * Patients with severe hepatic or renal insufficiency. * Patients with severe hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of postoperative deliriumParticipants will be followed for the duration of hospital stay, an expected average of 5 days.Participants will be followed for the duration of hospital stay, an expected average of 5 days.Evaluations are conducted twice a day.

Countries

China

Contacts

Primary ContactHao Li, Doctor
lihao301@126.com15010665099

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026